The European Patent Office (EPO) has granted patent EP3510146B1, titled "TRANSCRIPTION FACTORS CONTROLLING DIFFERENTIATION OF STEM CELLS." This patent, effective March 18, 2026, covers a specific biotechnological innovation related to the control of stem cell differentiation using transcription factors. The grant is a final determination of patentability for the invention, listing Alex H.M. Ng, George M. Church, and Volker Busskamp as inventors.

This patent grant primarily impacts entities involved in biotechnology research and development, particularly those working with stem cells and gene regulation. For compliance officers in the pharmaceutical and biotech sectors, this means understanding the scope of this patent to avoid infringement when developing related technologies or products. While this is a patent grant and not a regulatory rule imposing direct compliance obligations, it establishes intellectual property rights that can affect market exclusivity and commercialization strategies for related innovations.